About Multiple Sclerosis Foundation



Home > Learn About Multiple Sclerosis > News > Test may predict cognitive performance

Test may predict cognitive performance

10/9/2015

A new study suggests that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a promising cognitive screening tool to predict actual functional performance in MS patients.

Researchers, led by Dr. Yael Goverover, a visiting scientist at Kessler Foundation and associate professor at New York University, wanted to know whether the BICAMS can predict performance of activities of daily living using Actual Reality™ in persons with MS.

They compared 41 MS patients and 32 healthy controls performing BICAMS and an AR task. Participants were asked to access the Internet to purchase a flight ticket or cookies, and were given the BICAMS and questionnaires to assess quality of life, affect symptomatology, and prior Internet experience. What they found was that participants with MS performed significantly worse than controls on the BICAMS and the AR. Additionally, better BICAMS performance was associated with more independent AR performance.

According to Dr. Goverover, "BICAMS may be useful for predicting performance on everyday activities, as well as for assessing cognitive abilities. This finding has implications for clinicians who care for individuals with MS in a broad range of settings, especially those with limited access to neuropsychological consultation."

The findings were published in Multiple Sclerosis Journal.



  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 

 

Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved

�